Cargando…

Application of Distributed Parameter Model to Assessment of Glioma IDH Mutation Status by Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Previous studies using contrast-enhanced imaging for glioma isocitrate dehydrogenase (IDH) mutation assessment showed promising yet inconsistent results, and this study attempts to explore this problem by using an advanced tracer kinetic model, the distributed parameter model (DP). Fifty-five patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zongfang, Zhao, Wei, He, Bo, Koh, Tong San, Li, Yanxi, Zeng, Yizhen, Zhang, Zhuo, Zhang, Jingzhong, Hou, Zujun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704178/ https://www.ncbi.nlm.nih.gov/pubmed/33299387 http://dx.doi.org/10.1155/2020/8843084

Ejemplares similares

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
por: Wang, Hao-Yuan, et al.
Publicado: (2016)

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients
por: Choi, Changho, et al.
Publicado: (2012)

Stalled oligodendrocyte differentiation in IDH-mutant gliomas
por: Wei, Yanfei, et al.
Publicado: (2023)

Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023)

PDPN contributes to constructing immunosuppressive microenvironment in IDH wildtype glioma
por: Wang, Xuya, et al.
Publicado: (2022)

Transcriptional Characteristics of IDH-Wild Type Glioma Subgroups Highlight the Biological Processes Underlying Heterogeneity of IDH-Wild Type WHO Grade IV Gliomas
por: Chang, Yu-Zhou, et al.
Publicado: (2020)

Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma()()
por: Sun, Chao, et al.
Publicado: (2020)

Nuclear Magnetic Resonance Metabolic Fingerprint of Bevacizumab in Mutant IDH1 Glioma Cells
por: Mesti, Tanja, et al.
Publicado: (2018)

Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas
por: Leather, Thomas, et al.
Publicado: (2017)

Evaluation of tracer kinetic parameters in cervical cancer using dynamic contrast-enhanced MRI as biomarkers in terms of biological relevance, diagnostic performance and inter-center variability
por: Wang, Xue, et al.
Publicado: (2022)

Retrospective examination of pseudoprogression in IDH mutant gliomas
por: Wetzel, Ethan A, et al.
Publicado: (2023)

IDH mutation-specific radiomic signature in lower-grade gliomas
por: Liu, Xing, et al.
Publicado: (2019)

A comparative study of methods for determining Intravoxel incoherent motion parameters in cervix cancer
por: Wang, Xue, et al.
Publicado: (2021)

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

Promoter Methylation Analysis of IDH Genes in Human Gliomas
por: Flanagan, Simon, et al.
Publicado: (2012)

Matching Quantitative MRI Parameters with Histological Features of Treatment-Naïve IDH Wild-Type Glioma
por: Maurer, Gabriele D., et al.
Publicado: (2021)

IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma
por: Chen, Xueqin, et al.
Publicado: (2023)

Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas
por: Park, Chul-Kee, et al.
Publicado: (2015)

Characteristics of gliomas in patients with somatic IDH mosaicism
por: Bonnet, Charlotte, et al.
Publicado: (2016)

Updates on the WHO diagnosis of IDH-mutant glioma
por: Reuss, David.E.
Publicado: (2023)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

IDH mutations but not TERTp mutations are associated with seizures in lower-grade gliomas
por: Duan, Wen-chao, et al.
Publicado: (2018)

Analyses of metastasis-associated genes in IDH wild-type glioma
por: Li, Xiaozhi, et al.
Publicado: (2020)

Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins
por: Kaminska, Bozena, et al.
Publicado: (2019)

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)

CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021)

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas
por: Murugan, A. K., et al.
Publicado: (2022)

Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023)

Radiomic study on preoperative multi‐modal magnetic resonance images identifies IDH‐mutant TERT promoter‐mutant gliomas
por: Wang, Haoyu, et al.
Publicado: (2022)

A Comparative Study of Two-Compartment Exchange Models for Dynamic Contrast-Enhanced MRI in Characterizing Uterine Cervical Carcinoma
por: Wang, Xue, et al.
Publicado: (2019)

Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas
por: Liu, Yanwei, et al.
Publicado: (2022)

Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma
por: Fanucci, Kristina, et al.
Publicado: (2023)

Mutation Analysis of IDH1 in Paired Gliomas Revealed IDH1 Mutation Was Not Associated with Malignant Progression but Predicted Longer Survival
por: Yao, Yu, et al.
Publicado: (2013)

Non-Invasive Estimation of Glioma IDH1 Mutation and VEGF Expression by Histogram Analysis of Dynamic Contrast-Enhanced MRI
por: Hu, Yue, et al.
Publicado: (2020)

Insulator dysfunction and oncogene activation in IDH mutant gliomas
por: Flavahan, William A., et al.
Publicado: (2015)

IDH1 Mutation in Gliomas in Mosul City - Iraq
por: Saeed, Mohammed Sami
Publicado: (2015)

Metabolic Reprogramming in Mutant IDH1 Glioma Cells
por: Izquierdo-Garcia, Jose L., et al.
Publicado: (2015)

Mutant IDH1 Promotes Glioma Formation In Vivo
por: Philip, Beatrice, et al.
Publicado: (2018)

Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
por: Park, Jong-Whi, et al.
Publicado: (2019)

Pharmacoresistant seizures and IDH mutation in low-grade gliomas
por: Correia, Carlos Eduardo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_frpl7go5orb467o1n21u1ij8hs